ClinicalTrials.gg
RecruitingNCT06650566Updated May 2, 2025

Study of LM-299 in Subjects Advanced Malignant Tumors

A Phase 1/2 interventional study of LM-299 in Malignant Tumors, sponsored by LaNova Medicines Limited. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-299 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explorethe recommended dose for expansion (RDE) in patients with advanced solid tumours..

For Phase II Dose Expansion Stage, to assess the antitumor activity of LM-299 in patients with various advanced solid tumors.

02

Conditions studied

  • Malignant Tumors

Browse trials for

03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 108 is above the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are willing to participate in the study and sign the form (ICF) prior to any procedure.
  2. Participant must be 18- 18 years or the legal age of consent at the time of signing the ICF.
  3. (ECOG) performance status of 0-1.
  4. ≥ 3 months.
  5. Patients with advanced solid tumors confirmed by histopathological diagnosis who have failed standard treatment, are intolerant to standard treatment, or for whom standard treatment is currently unsuitable.
  6. Pre-treatment archived tumour tissue (within 5 years) or fresh samples could be provided for biomarker analysis.
  7. Must have at least one according to v1.1.
  8. Adequate organ and bone marrow function as defined by protocol.
  9. Female subjects of or male subjects with partners of childbearing potential agree to use highly effective .
  10. Subjects who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Participate in any other clinical trial within 28 days prior to 1st dosing of LM-299.
  2. Subjects who have received the anti-tumor treatments within the specified time periods prior to the first dosing of LM-299.
  3. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of v5.0.
  4. Subjects with uncontrolled tumour-related pain.
  5. Subjects with known central nervous system (CNS) or meningeal .
  6. Qualitative urine protein results ≥ 3+.
  7. hemoptysis or tumor bleeding within 2 weeks prior to 1st dosing of LM-299.
  8. Any life-threatening bleeding event that occurred within 3 months prior to 1st dosing of LM-299.
  9. Subjects with esophageal or gastric varices requiring immediate intervention or a history of variceal bleeding .
  10. Hepatic encephalopathy, hepatorenal syndrome, or class B or more severe liver cirrhosis.
  11. Subjects who have clinically uncontrollable third-space fluid accumulatio.
  12. Radiographic evidence of tumor invading surrounding vital organs or the risk of esophagotracheal fistula or esophagopleural fistula, tumor surrounding or invading the major blood vessels, or presence of intratumoral cavity formation.
  13. History of gastrointestinal perforation and/or fistula within 6 months prior to the first dose of the study drug.
  14. Patients with complete or incomplete intestinal obstruction within 3 months prior to the first dose of the study drug or patientswho are currently at the risk of intestinal perforation.
  15. Subjects who are known to be allergic to antibody treatment.
  16. Subjects who take systemic (≥ 10 mg/day of prednisone or equivalent) for more than 7 days within 2 weeks prior to the first dose of LM-299.
  17. Subjects with the known history of disease.
  18. Patients with a history of active or previously confirmed inflammatory bowel disease.
  19. Patients with a history of or currently having interstitial pneumonia requiring systemic corticosteroid treatment.
  20. Received or attenuated live vaccines within 28 days prior to the first dose of the study drug.
  21. Currently using anticoagulants such as therapeutic doses of heparin or vitamin K antagonists.
  22. Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-299 (excluding tumour , puncture, etc.).
  23. Subjects who have severe cardiovascular and and cerebrovascular diseases.
  24. Patients with severe infections within 4 weeks prior to the first dose.
  25. Patients with a history of immunodeficiency.
  26. Individuals with infection, active or infection .
  27. Patients with known active tuberculosis (TB). Suspected active TB should be ruled out through clinical examination.
  28. Patients who have had other within 5 years prior to the first dose of the study drug.
  29. Women of childbearing age who test positive for pregnancy within 7 days prior to the first dose of the study drug or are breastfeeding.
  30. Individuals with known psychiatric disorders or illnesses that may affect adherence to the trial.
  31. Patients with local or systemic diseases caused by non-malignant tumors.
  32. Subject who is judged as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    LM-299 Dose Escalation at different dose levels

    Drug: LM-299

  • Experimental
    LM-299 Dose Escalation Backfill Cohorts

    Drug: LM-299

Interventions

  • DrugLM-299

    Q2W/Q3W,Intravenous Drip

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limitingtoxicity (DLT)

    Phase 1

    Time frame: 53 weeks

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Phase 1

    Time frame: 53 weeks

  3. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Phase 1

    Time frame: 53 weeks

  4. Overall Response Rate (ORR)

    Phase 2

    Time frame: 50 weeks

Secondary outcomes

  1. PK Parameter: Area Under the Concentration-time Curve(AUClast)

    Phase 1 and 2

    Time frame: 103 weeks

  2. PK Parameter: Area Under the Concentration-time Curve(AUCtau)

    Phase 1 and 2

    Time frame: 103 weeks

  3. Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)

    Phase 1 and 2

    Time frame: 103 weeks

  4. PK Parameter:Time of Maximum Observed Concentration (Tmax)

    Phase 1 and 2

    Time frame: 103 weeks

  5. PK Parameter: Elimination Half-life (t1/2)

    Phase 1 and 2

    Time frame: 103 weeks

  6. PK Parameter: Steady State Maximum Concentration(Cmax,ss)

    Phase 1 and 2

    Time frame: 103 weeks

  7. PK Parameter: Steady State Minimum Concentration(Cmin,ss)

    Phase 1 and 2

    Time frame: 103 weeks

  8. PK Parameter: Systemic Clearance at Steady State (CLss)

    Phase 1 and 2

    Time frame: 103 weeks

  9. PK Parameter: Volume of Distribution at Steady-State (Vss)

    Phase 1 and 2

    Time frame: 103 weeks

  10. PK Parameter: Accumulation Ratio (Rac AUC)

    Phase 1 and 2

    Time frame: 103 weeks

  11. PK Parameter: Degree of Fluctuation (DF)

    Phase 1 and 2

    Time frame: 103 weeks

  12. Overall Response Rate (ORR)

    Phase 1

    Time frame: 53 weeks

  13. Duration of Response (DOR) in Month

    Phase 1 and 2

    Time frame: 103 weeks

  14. Disease control rate (DCR) in percentage

    Phase 1 and 2

    Time frame: 103 weeks

  15. progression-free survival (PFS) in Month

    Phase 1 and 2

    Time frame: 103 weeks

  16. Overall survival (OS) in Month

    Phase 1 and 2

    Time frame: 103 weeks

  17. PK Parameter: Accumulation Ratio (Rac Cmax)

    Phase 1 and 2

    Time frame: 103 weeks

07

Study locations

1 of 6 sites recruiting
  • One Clinical Research
    Perth, West Australia, Australia
    Not yet recruiting
    • Dr Mihitha Ariyapperuma · Contact
  • the first affiliated hospital of Xinxiang medical University
    Xinxiang, Henan, China
    Not yet recruiting
    • Weizheng Kou · Contact
  • Liaocheng people's hospital
    Liaocheng, Shandong, China
    Not yet recruiting
    • Baozhong Wang · Contact
  • Zibo municipal hospital
    Zibo, Shandong, China
    Not yet recruiting
    • Rusen Zhao · Contact
  • Shanghai Dongfang Hospital (Tongji University Affiliated Dongfang Hospital)
    Shanghai, Shanghai, China
    Not yet recruiting
    • Junli Xue · Contact
  • Shanghai GoBroad Cancer Hospital China Pharmaceutical University
    Shanghai, Shanghai, China
    Recruiting
    • Jin Li · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 26 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 21, 2024
StartActual
Oct 9, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jul 2027
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06650566
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Oct 9, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
May 2, 2025

Study contacts

Alex Yuan
Contact
alexyuan@lanovamed.com
+8615901815211

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010

Start the discussion